Salofalc, rectal suspension 4 g/60 ml 60 ml 7 pcs

Salofalc has anti-inflammatory action.

Inhibits the synthesis of arachidonic acid (AG) metabolites, activity of neutrophil lipooxygenase, inhibits migration, degranulation and phagocytosis of neutrophils, immunoglobulin secretion by lymphocytes; binds and destroys free oxygen radicals.

Indications

Ulcerative colitis, Crohn’s disease.

Active ingredient

Composition

1 vial contains 4 g of mesalazine.

How to take, the dosage

Rectally in proctitis, proctosigmoiditis and left-sided ulcerative colitis to treat exacerbations use enemas (60 or 30 ml of suspension depending on the extent of the lesion) once a day before bedtime (first the bowel should be cleaned).

For prevention of recurrence of ulcerative colitis limited to the lesion of the rectum, it is usually effective to use suppositories for 250 mg 3 times a day.

Interaction

When concomitant administration may increase the effect of coumarin anticoagulants, increased toxicity of methotrexate, decreased diuretic effect of spironolactone and furosemide, decreased effectiveness of probenecid and rifampicin.

It enhances hypoglycemic effect of oral antidiabetic agents – sulfonylurea derivatives.

Special Instructions

Salofalc is recommended to be used only under the supervision of a doctor.

Blood and urine tests should be performed before treatment, during therapy (14 days after the start of therapy and then every 4 weeks), and after the end of therapy (every 3 months).

In order to control kidney function it is recommended to determine serum urea and creatinine levels, urine sediment examination.

Contraindications

Hypersensitivity, blood diseases, liver failure, children (under 2 years).

Side effects

Rarely – abdominal pain, diarrhea, flatulence, headache and dizziness, allergic reactions, in single cases – interstitial nephritis, systemic lupus erythematosus, methemoglobinemia, thrombocytopenia.

Similarities